-
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
Friday, May 14, 2021 - 3:40pm | 266Read More...Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The biotech will start trading on NASDAQ from Monday under the ticker “VERA.” Vera’s lead candidate...
-
Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease
Monday, March 15, 2021 - 6:45am | 272Read More...Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (IgAN). IgAN, also known as Berger's disease, is a kidney disease that...
-
Calliditas Starts Dosing In Nefecon Open Label Extension Study In Kidney Disease
Thursday, February 4, 2021 - 9:05am | 317Read More...Calliditas Therapeutics AB (NASDAQ: CALT) has dosed that first patient in the global open-label extension part of Phase 3 study (dubbed as NefIgArd) that will offer a 9-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will...
